IVA Stock Overview
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||€8.83|
|52 Week High||€13.18|
|52 Week Low||€8.30|
|1 Month Change||-10.08%|
|3 Month Change||-18.24%|
|1 Year Change||-24.01%|
|3 Year Change||267.92%|
|5 Year Change||16.95%|
|Change since IPO||2.91%|
Recent News & Updates
|IVA||FR Biotechs||FR Market|
Return vs Industry: IVA exceeded the French Biotechs industry which returned -39% over the past year.
Return vs Market: IVA underperformed the French Market which returned -5.4% over the past year.
|IVA Average Weekly Movement||3.9%|
|Biotechs Industry Average Movement||8.9%|
|Market Average Movement||6.1%|
|10% most volatile stocks in FR Market||10.5%|
|10% least volatile stocks in FR Market||3.6%|
Stable Share Price: IVA is less volatile than 75% of French stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: IVA's weekly volatility (4%) has been stable over the past year.
About the Company
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease.
Inventiva Fundamentals Summary
|IVA fundamental statistics|
Is IVA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IVA income statement (TTM)|
|Cost of Revenue||€1.02m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.21|
|Net Profit Margin||-583.87%|
How did IVA perform over the long term?See historical performance and comparison
Is Inventiva undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IVA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IVA's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: IVA is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: IVA is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IVA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IVA is overvalued based on its PB Ratio (4.1x) compared to the FR Biotechs industry average (2.6x).
How is Inventiva forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IVA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IVA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IVA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IVA's revenue (63.9% per year) is forecast to grow faster than the French market (5.8% per year).
High Growth Revenue: IVA's revenue (63.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IVA's Return on Equity is forecast to be high in 3 years time
How has Inventiva performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IVA is currently unprofitable.
Growing Profit Margin: IVA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IVA is unprofitable, and losses have increased over the past 5 years at a rate of 22.3% per year.
Accelerating Growth: Unable to compare IVA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IVA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: IVA has a negative Return on Equity (-55.85%), as it is currently unprofitable.
How is Inventiva's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: IVA's short term assets (€115.6M) exceed its short term liabilities (€22.9M).
Long Term Liabilities: IVA's short term assets (€115.6M) exceed its long term liabilities (€10.3M).
Debt to Equity History and Analysis
Debt Level: IVA has more cash than its total debt.
Reducing Debt: IVA's debt to equity ratio has increased from 1.7% to 11.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IVA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IVA has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 18.3% each year.
What is Inventiva current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IVA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IVA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IVA has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Frederic Cren (55 yo)
Mr. Frederic Cren has been Chief Executive Officer of Inventiva S.A. since co-founding Inventiva S.A. in 2011. Mr. Cren has been Chairman at Inventiva S.A. since May 31, 2016. He served as President of Inv...
CEO Compensation Analysis
Compensation vs Market: Frederic's total compensation ($USD992.51K) is above average for companies of similar size in the French market ($USD456.58K).
Compensation vs Earnings: Frederic's compensation has increased whilst the company is unprofitable.
Experienced Management: IVA's management team is seasoned and experienced (9.8 years average tenure).
Experienced Board: IVA's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.8%.
Inventiva S.A.'s employee growth, exchange listings and data sources
- Name: Inventiva S.A.
- Ticker: IVA
- Exchange: ENXTPA
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €360.787m
- Shares outstanding: 40.86m
- Website: https://www.inventivapharma.com
Number of Employees
- Inventiva S.A.
- 50 rue de Dijon
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/23 00:00|
|End of Day Share Price||2022/05/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.